421 Kipling Street
Palo Alto, California 94301
Eidos Therapeutics is developing a drug candidate, AG10, to treat both forms of TTR amyloidosis. AG10 is a small molecule that binds and stabilizes TTR in the blood, preventing the formation of amyloid and potentially halting progression of the disease. Eidos’ scientific co-founders discovered AG10 with funding from Stanford Medicine’s TRAM and SPARK programs using the latest precision medicine techniques for drug discovery. The therapeutic candidate is now being guided by Eidos’ experienced team of scientists and clinicians, and will enter Phase 1 clinical trials in 2017.